Trending Stocks: Celgene Corporation (NASDAQ:CELG), Red Hat Inc (NYSE:RHT), Cognizant Technology Solutions (NASDAQ:CTSH), Finisar Corporation (NASDAQ:FNSR)

Celgene Corporation (NASDAQ:CELG) announced on Friday, March 21, 2014 that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis. A chronic disorder, psoriatic arthritis is characterized by pain, stiffness, swelling and tenderness of the joints, inflammation of specific ligaments and tendons, and a decrease in physical functioning. OTEZLA is the only FDA-approved oral treatment for psoriatic arthritis. Celgene Corporation (NASDAQ:CELG) shares after opening at $142.00 on last trade day and at the end of the day closed at $142.22. Company price to sales ratio in past twelve months was calculated as 9.00 and price to cash ratio as 10.28. Celgene Corporation (NASDAQ:CELG) showed a negative weekly performance of -5.19%.

Red Hat Inc (NYSE:RHT)shares declined 1.1% to $55.50, swinging from an earlier after-hours gain, on moderate volume after the software company reported sales and revenue for the fourth quarter that topped Wall Street estimates. Red Hat Inc (NYSE:RHT) shares fell 0.27% in last trading session and ended the day on $56.13. RHT return on equity ratio is recorded as 12.10% and its return on assets is 6.40%. Red Hat Inc (NYSE:RHT) yearly performance is 76787%.

Cognizant Technology Solutions Corp (NASDAQ:CTSH) was upgraded by analysts at Morgan Stanley from an equal rating to a weight rating. The firm currently has $60.00 target price on the stock. Cognizant Technology Solutions Corp (NASDAQ:CTSH) shares moved down -3.10% in last trading session and was closed at $47.58, while trading in range of $ 3.48 – 3.60. Cognizant Technology Solutions Corp (NASDAQ:CTSH) year to date (YTD) performance is -5.76%.

Finisar (NASDAQ:FNSR) was upgraded by investment analysts at RBC Capital from a “sector perform” rating to an “outperform” rating in a note issued to investors on Friday, AR Network reports. The firm currently has a $30.00 price target on the stock, up from their previous price target of $26.00. RBC Capital’s price objective would indicate a potential upside of 17.46% from the stock’s previous close. Finisar Corporation (NASDAQ:FNSR) weekly performance is -3.80%. On last trading day company shares ended up $25.52. Finisar Corporation (NASDAQ:FNSR)distance from 50-day simple moving average (SMA50) is 6.82%. Analysts mean target price for the company is $28.32.